Advertisement

AAPS PharmSci

, Volume 2, Issue 1, pp 29–41 | Cite as

Pharmacogenomics: The promise of personalized medicine

  • Laviero Mancinelli
  • Maureen Cronin
  • Wolfgang SadéeEmail author
Article

Abstract

Pharmacogenetics and pharmacogenomics deal with the genetic basis underlying variable drug response in individual patients. The traditional pharmacogenetic approach relies on studying sequence variations in candidate genes suspected of affecting drug response. On the other hand, pharmacogenomic studies encompass the sum of all genes, i.e., the genome. Numerous genes may play a role in drug response and toxicity, introducing a daunting level of complexity into the search for candidate genes. The high speed and specificity associated with newly emerging genomic technologies enable the search for relevant genes and their variants to include the entire genome. These new technologies have essentially spawned a new discipline, termed pharmacogenomics, which seeks to identify the variant genes affecting the response to drugs in individual patients. Moreover, pharmacogenomic analysis can identify disease susceptibility genes representing potential new drug targets. All of this will lead to novel approaches in drug discovery, an individualized application of drug therapy, and new insights into disease prevention. Current concepts in drug therapy often attempt treatment of large patient populations as groups, irrespective of the potential for individual, genetically-based differences in drug response. In contrast, pharmacogenomics may help focus effective therapy on smaller patient subpopulations which although demonstrating the same disease phenotype are characterized by distinct genetic profiles. Whether and to what extent this individual, genetics-based approach to medicine results in improved, economically feasible therapy remain to be seen.

To exploit these opportunities in genetic medicine, novel technologies will be needed, legal and ethical questions must be clarified, health care professionals must be educated, and the public must be informed about the implications of genetic testing in drug therapy and disease management.

Key Words

Pharmacogenomics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279:1200–1205.PubMedCrossRefGoogle Scholar
  2. 2.
    Sadee W. Finding the right drug for the right patient. Pharm Res. 1998;15:959–963.PubMedCrossRefGoogle Scholar
  3. 3.
    Maynard Smith J. The Theory of Evolution. Baltimore, Maryland: Penguin Books; 1962.Google Scholar
  4. 4.
    Garrod AE. The incidence of alcaptonuria: a study in chemical individuality. Lancet. 1902;ii:1616–1620.CrossRefGoogle Scholar
  5. 5.
    Snyder LH. Studies in human inheritance. Ohio J Sci. 1932;32:436–468.Google Scholar
  6. 6.
    Ford EB. Genetic Polymorphism. London: Faber & Faber; 1965.Google Scholar
  7. 7.
    Nebert DW. Pharmacogenetics: 65 candles on the cake. Pharmacogenetics. 1997;7:435–440.CrossRefGoogle Scholar
  8. 8.
    Kalow W. Pharmacogenetics: heredity and the response to drugs. Philadelphia: W. B. Saunders; 1962.Google Scholar
  9. 9.
    Carsen PE, Flanagan CL, Iokes CE, Alving AS. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956;124,484–485.CrossRefGoogle Scholar
  10. 10.
    Hughes HB, Biehl JP, Jones AP, Schmidt LH. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberculosis. 1954;70:266–273.Google Scholar
  11. 11.
    Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J. 1960;2:485–490.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Vatsis K, Martell KJ, Weber WW. Proc Natl Acad Sci U S A. 1991;88:6333.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Motulsky AG. Drug reactions, enzymes and biochemical genetics. JAMA. 1957;165:835–837.CrossRefGoogle Scholar
  14. 14.
    Eichelbaum M, Steincke B, Dengler JJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1977;16:183–187.CrossRefGoogle Scholar
  15. 15.
    Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651–62.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Tai H, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet. 1996;58:694–702.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Goldenberg MM. Transtuzumab, a recombinant DNA derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Therapeut. 1999;21:309–318.CrossRefGoogle Scholar
  18. 18.
    Baselge J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (HERCEPTIN) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xeno-grafts. Cancer Res. 1998;58:2825–2831.Google Scholar
  19. 19.
    Touw DJ. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P450 enzymes. Drug Metab Drug Interact. 1997;14:55–82.Google Scholar
  20. 20.
    Evans DAP. Genetic factors in drug therapy. In: Clinical and Molecular Pharmacogenetics. Cambridge: Cambridge University Press; 1993.Google Scholar
  21. 21.
    Buchert E, Woosley RL. Clinical implications of variable antiarrythmic drug metabolism. Pharmacogenet. 1992;2:2–11.CrossRefGoogle Scholar
  22. 22.
    Dahl AK, Bertilsson, L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenet. 1993;3:61–70.CrossRefGoogle Scholar
  23. 23.
    Tanaka E, Hisawa S. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressents and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther. 1999;24:7–16.PubMedCrossRefGoogle Scholar
  24. 24.
    de Morais S, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419–15422.PubMedGoogle Scholar
  25. 25.
    Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med. 1995;73:39–553.CrossRefGoogle Scholar
  26. 26.
    Gonzales FJ. Pharmacogenetic phenytyping and genotyping. Present status and future potential. Clin Pharmacokinet. 1994;26:59–70.CrossRefGoogle Scholar
  27. 27.
    Ball SE, Scatina JA, Sisenwine SF, Fisher GL. The application of in vitro models of drug metabolism and toxicity in drug discovery and drug development. Drug Chem Toxicity. 1995;18:1–28.CrossRefGoogle Scholar
  28. 28.
    Guengerich F. The Environmental Genome Project: Functional analysis of polymorphisms. Environment Health Perspect. 1998;106:365–368.CrossRefGoogle Scholar
  29. 29.
    Kleyn PW, Vesell ES. Genetic variation as a guide to drug development. Science. 1998;281:1820–1821.PubMedCrossRefGoogle Scholar
  30. 30.
    Sadee W. Pharmacogenomics. BMJ. 1999;319:1286.PubMedCentralCrossRefGoogle Scholar
  31. 31.
    Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487–491.PubMedCrossRefGoogle Scholar
  32. 32.
    Iyer VR, Eisen MB, Ross DT, et al. The transcriptional program in the response of human fibroblasts to serum. Science. 1999;283,83–87.PubMedCrossRefGoogle Scholar
  33. 33.
    Schachter B. Pharming the Genome. Biomednet [serial online]. October 30, 1998;41.Google Scholar
  34. 34.
    Fluri KG, Fitzpatrick G, Chiem N, Harrison DJ. Integrated capillary electrophoresis devices with an efficient postcolumn reactor in planar quartz and glass chips. Anal Chem. 1996;68:4285–4290.PubMedCrossRefGoogle Scholar
  35. 35.
    Jacobson SC, Ramsey SC. Integrated microdevice for DNA restriction fragment analysis. Anal Chem. 1996;68:720–723.PubMedCrossRefGoogle Scholar
  36. 36.
    Blanchard AP, Friend SH. Cheap DNA arrays-it’s not all smoke and mirrors. Nature Biotech. 1999;17:953.CrossRefGoogle Scholar
  37. 37.
    Russo E. Big pharma hedges its bets. The Scientist. 1999;13:1.Google Scholar
  38. 38.
    Poste G. In Bio ’98 International Meeting and Exposition 1–9. New York: RAND Corporation; 1999.Google Scholar
  39. 39.
    Weber WW. Pharmacogenetics. New York: Oxford University Press; 1997.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2002

Authors and Affiliations

  • Laviero Mancinelli
    • 1
  • Maureen Cronin
    • 1
  • Wolfgang Sadée
    • 2
    Email author
  1. 1.ACLARA Biosciences, Inc.Santa Clara
  2. 2.Department of Biopharmaceutical Sciences and Pharmaceutical ChemistryUniversity of California San FranciscoSan Francisco

Personalised recommendations